[go: up one dir, main page]

AR019011A1 - Inhibidores de las caspasas, composiciones farmaceuticas que comprenden estos inhibidores, metodos para inhibir la actividad de caspasa, disminuir laproduccion de 161f, disminuir la produccion de ifn-gama y para tratar interleukina 1, enfermedades mediadas por apoptosis e interferon-gama usando dich - Google Patents

Inhibidores de las caspasas, composiciones farmaceuticas que comprenden estos inhibidores, metodos para inhibir la actividad de caspasa, disminuir laproduccion de 161f, disminuir la produccion de ifn-gama y para tratar interleukina 1, enfermedades mediadas por apoptosis e interferon-gama usando dich

Info

Publication number
AR019011A1
AR019011A1 ARP990101240A ARP990101240A AR019011A1 AR 019011 A1 AR019011 A1 AR 019011A1 AR P990101240 A ARP990101240 A AR P990101240A AR P990101240 A ARP990101240 A AR P990101240A AR 019011 A1 AR019011 A1 AR 019011A1
Authority
AR
Argentina
Prior art keywords
production
inhibitors
decrease
methods
compounds
Prior art date
Application number
ARP990101240A
Other languages
English (en)
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of AR019011A1 publication Critical patent/AR019011A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Crystallography & Structural Chemistry (AREA)

Abstract

La presente invencion está relacionada con clases novedosas de compuestos que son inhibidores de las caspasas, en particular inhibidores de la enzima deconversion de la interleuquina-1-beta(ECI). Esta invencion también está relacionada con composiciones farmacéuticas que comprenden estos compuestos. Loscompuestos y composiciones farmacéuticas de esta invencion particularmente son bastante adecuadas para la inhibicion de la actividad de la caspasa y enconsecuencia, pueden ser usados ventajosamente como agentes contra las enfermedades mediadas por la interleuquina-1(II-1), apoptosis, factor de induccion delinterferon - gamma (FIIG), o interferon - gamma, incluyendo enfermedades inflamatorias, enfermedades auto-inmunes, desordenes oseos destructivos, desordenesproliferativos, enfermedades infecciosas, y enfermedades degenerativas. Esta invencion también está relacionada con métodos para la inhibicion de la actividadde la caspasa y disminucion de la produccion de FIIG y la produccion de IFN-GAMA y métodos para el tratamiento de enfermedades mediadas por la interleuquina-1(IL-1), apoptosis, e interferon-gamma que usan los compuestos y composiciones de esta invencion. Esta invencion también está relacionada con métodos depreparacion delos compuestos de esta invencion.
ARP990101240A 1998-03-19 1999-03-19 Inhibidores de las caspasas, composiciones farmaceuticas que comprenden estos inhibidores, metodos para inhibir la actividad de caspasa, disminuir laproduccion de 161f, disminuir la produccion de ifn-gama y para tratar interleukina 1, enfermedades mediadas por apoptosis e interferon-gama usando dich AR019011A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7877098P 1998-03-19 1998-03-19

Publications (1)

Publication Number Publication Date
AR019011A1 true AR019011A1 (es) 2001-12-26

Family

ID=22146109

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990101240A AR019011A1 (es) 1998-03-19 1999-03-19 Inhibidores de las caspasas, composiciones farmaceuticas que comprenden estos inhibidores, metodos para inhibir la actividad de caspasa, disminuir laproduccion de 161f, disminuir la produccion de ifn-gama y para tratar interleukina 1, enfermedades mediadas por apoptosis e interferon-gama usando dich

Country Status (33)

Country Link
US (3) US6531474B1 (es)
EP (6) EP2261235A3 (es)
JP (3) JP4594520B2 (es)
KR (2) KR100898094B1 (es)
CN (1) CN1321129C (es)
AP (1) AP2000001919A0 (es)
AR (1) AR019011A1 (es)
AT (1) ATE410439T1 (es)
AU (1) AU769033B2 (es)
BG (1) BG104863A (es)
BR (2) BRPI9909660B8 (es)
CA (1) CA2324226C (es)
CZ (1) CZ302281B6 (es)
DE (1) DE69939689D1 (es)
DK (1) DK1064298T3 (es)
ES (1) ES2315010T3 (es)
GE (1) GEP20043163B (es)
HU (1) HU227920B1 (es)
ID (1) ID27002A (es)
IL (3) IL138469A0 (es)
IS (1) IS5622A (es)
NO (1) NO331829B1 (es)
NZ (2) NZ528282A (es)
PL (1) PL204619B1 (es)
PT (1) PT1064298E (es)
RU (1) RU2274642C2 (es)
SI (1) SI1064298T1 (es)
SK (1) SK286736B6 (es)
TR (1) TR200103406T2 (es)
TW (1) TWI243828B (es)
UA (2) UA74133C2 (es)
WO (1) WO1999047545A2 (es)
ZA (1) ZA200004652B (es)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244677B2 (en) 1998-02-04 2007-07-17 Semitool. Inc. Method for filling recessed micro-structures with metallization in the production of a microelectronic device
ID27002A (id) * 1998-03-19 2001-02-22 Vertex Pharma Penghambat-penghambat kaspase
US7157430B2 (en) 1998-10-22 2007-01-02 Idun Pharmaceuticals, Inc. (Substituted)acyl dipeptidyl inhibitors of the ICE/CED-3 family of cysteine proteases
US6242422B1 (en) 1998-10-22 2001-06-05 Idun Pharmacueticals, Inc. (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
US7326542B2 (en) 1998-12-02 2008-02-05 Princeton University Compositions and methods for regulating bacterial pathogenesis
US6720415B2 (en) 1998-12-02 2004-04-13 Princeton University Compositions and methods for regulating bacterial pathogenesis
WO2001027085A1 (en) * 1999-10-13 2001-04-19 Merck Frosst Canada & Co. Nicotinyl aspartyl ketones as inhibitors of caspase-3
US6395767B2 (en) * 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US6525024B1 (en) 2000-04-17 2003-02-25 Idun Pharmaceuticals, Inc. Inhibitors of the ICE/ced-3 family of cysteine proteases
US6559176B1 (en) 2000-05-10 2003-05-06 Princeton University Compounds and methods for regulating bacterial growth and pathogenesis
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
PE20020500A1 (es) * 2000-09-13 2002-06-25 Vertex Pharma Derivados de piperidina, tetrahidroquinolina, tetrahidroisoquinolina como inhibidores de caspasas
US20030039661A1 (en) * 2001-03-02 2003-02-27 Teresa Aja Methods, compositions and kits for preserving antigenicity
PL222211B1 (pl) 2001-06-26 2016-07-29 Amgen Fremont Inc Przeciwciało przeciwko OPGL, kompozycja je zawierająca, jego zastosowanie i sposób jego wytwarzania, sposób wykrywania poziomu OPGL, kompozycja obejmująca polinukleotydy i komórka gosodarza
US7410956B2 (en) * 2002-02-11 2008-08-12 Vertex Pharmaceuticals Incorporated Caspase inhibitor prodrugs
EP1483241A4 (en) 2002-03-08 2006-12-13 Bristol Myers Squibb Co CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
FR2839309B1 (fr) 2002-05-03 2004-07-23 Aventis Pharma Sa Nouveaux derives de l'acide hexahydro-pyridazine-3- carboxylique, chimiotheques les contenant, leur utilisation comme medicaments, compositions pharmaceutiques les contenant et leurs procedes de preparation
US7001899B2 (en) 2002-06-10 2006-02-21 The Procter & Gamble Company Interleukin converting enzyme inhibitors
WO2004022536A1 (en) * 2002-09-04 2004-03-18 Glenmark Pharmaceuticals Limited New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
US7438910B2 (en) 2002-09-06 2008-10-21 Amgen Inc. Therapeutic human anti-IL1-R1 monoclonal antibody
AU2003269317B2 (en) 2002-10-23 2009-10-29 Glenmark Pharmaceuticals Ltd. Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
FR2846969A1 (fr) * 2002-11-08 2004-05-14 Salles Jean Pierre Nouveaux vecteurs moleculaires amphiphiles fluorocarbones a usage biomedical et medical
FR2847160A1 (fr) * 2002-11-20 2004-05-21 Oreal Composition capillaire contenant un compose pyrasol-carboxamide, son utilisation pour stimuler la pousse des cheveux et/ou freiner leur chute
EP1565150A1 (fr) * 2002-11-20 2005-08-24 L'oreal Utilisation d'un compose pyrazolcarboxamide pour stimuler la pousse des fibres keratiniques et/ou freiner leur chute
PL378813A1 (pl) 2003-04-11 2006-05-29 Glenmark Pharmaceuticals S.A. Nowe związki heterocykliczne przydatne w leczeniu stanów zapalnych i zaburzeń alergicznych: sposób ich wytwarzania i kompozycje farmaceutyczne zawierające te związki
AU2003902704A0 (en) * 2003-05-29 2003-06-19 Crc For Waste Management And Pollution Control Limited Of Unsw Process for producing a nanoscale zero-valent metal
AU2004294343A1 (en) * 2003-12-01 2005-06-16 Vertex Pharmaceuticals Incorporated Treating infectious diseases using ICE inhibitors
ES2320643T3 (es) * 2003-12-12 2009-05-27 Dr. Straetmans Chemische Produkte Gmbh Composiciones con acido anisico y gliceridos.
CN1942466B (zh) * 2004-02-27 2011-02-23 沃泰克斯药物股份有限公司 天冬氨酸特异性半胱氨酸蛋白酶抑制剂及其用途
EP1718639A2 (en) 2004-02-27 2006-11-08 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
AU2011226946B2 (en) * 2004-02-27 2012-05-03 Vertex Pharmaceuticals Incoporated Caspase Inhibitors and Uses Thereof
KR101135765B1 (ko) * 2004-03-12 2012-04-23 버텍스 파마슈티칼스 인코포레이티드 아스파르트산 아세탈 카스파아제 억제제의 제조를 위한방법 및 중간체
AU2012200214B2 (en) * 2004-05-14 2013-10-24 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US8273794B2 (en) * 2004-05-14 2012-09-25 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
EP1750689A1 (en) 2004-05-15 2007-02-14 Vertex Pharmaceuticals Incorporated Treating seizures using ice inhibitors
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
EP2295054A1 (en) 2004-05-27 2011-03-16 Vertex Pharmaceuticals Incorporated Ice inhibitors for the treatment of autoinflammatory diseases
DK1778718T3 (da) * 2004-07-02 2014-11-10 Genentech Inc Iap-inhibitorer
EP2457895A1 (en) * 2004-07-12 2012-05-30 Idun Pharmaceuticals, Inc. Tetrapeptide analogs
ATE402709T1 (de) * 2004-09-17 2008-08-15 Biomas Ltd Neue tellurium-verbindungen und ihre verwendung als immunmodulatoren
AR051933A1 (es) 2004-10-13 2007-02-21 Glenmark Pharmaceuticals Sa Proceso para la preparacion de n-(3,5 dicloropirid-4-ilo)-4-difluormetoxi-8-metano sulfonamido-dibenzo[b,d] furano-1-carboxamida
CN101124229B (zh) 2004-12-17 2012-07-18 格兰马克药品股份有限公司 用于治疗炎性和过敏性障碍的新杂环化合物
AU2005315319B2 (en) 2004-12-17 2011-07-07 Glenmark Pharmaceuticals S.A. Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders
JP4673068B2 (ja) * 2005-01-19 2011-04-20 独立行政法人科学技術振興機構 Ｔｈ１型アレルギー疾患治療用組成物
DE102005017116A1 (de) 2005-04-13 2006-10-26 Novartis Ag Hemmstoffe für Inhibitoren von Apoptose Proteinen (IAP)
CA2616337A1 (en) 2005-07-28 2007-02-08 Vertex Pharmaceuticals Incorporated Caspase inhibitor prodrugs
TW200736277A (en) 2005-11-14 2007-10-01 Amgen Inc RANKL antibody-PTH/PTHrP chimeric molecules
CA2656487A1 (en) * 2006-07-07 2008-01-17 The Board Of Trustees Of The Leland Stanford Junior University Selective caspase inhibitors
CN101534824A (zh) * 2006-11-17 2009-09-16 艾博特公司 作为化学活素受体拮抗剂的氨基吡咯烷
US8084862B2 (en) * 2007-09-20 2011-12-27 International Business Machines Corporation Interconnect structures with patternable low-k dielectrics and method of fabricating same
US7709370B2 (en) * 2007-09-20 2010-05-04 International Business Machines Corporation Spin-on antireflective coating for integration of patternable dielectric materials and interconnect structures
US8618663B2 (en) 2007-09-20 2013-12-31 International Business Machines Corporation Patternable dielectric film structure with improved lithography and method of fabricating same
WO2009124265A1 (en) * 2008-04-03 2009-10-08 The Board Of Trustees Of The Leland Stanford Junior University Probes for in vivo targeting of active cysteine proteases
US20110142902A1 (en) * 2008-05-27 2011-06-16 Imperial Innovations Limited Hypoxia Inducing Factor (HIF) Stabilising Glasses
US20110152343A1 (en) * 2009-12-22 2011-06-23 Functional Genetics, Inc. Protease inhibitors and broad-spectrum antiviral
GB201001070D0 (en) 2010-01-22 2010-03-10 St George's Hospital Medical School Theraputic compounds and their use
WO2011094426A1 (en) * 2010-01-29 2011-08-04 The United State Of America, As Represented By The Secretary, Department Of Health & Human Services Caspase inhibitors
GB201011411D0 (en) 2010-07-06 2010-08-18 St Georges Hosp Medical School Therapeutic compounds and their use
WO2012061786A1 (en) 2010-11-05 2012-05-10 Brandeis University Ice cleaved alpha-synuclein a biomarker
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
PL2766346T3 (pl) 2011-10-14 2017-09-29 Bristol-Myers Squibb Company Podstawione związki tetrahydroizochinoliny jako inhibitory czynnika XIA
JP6033318B2 (ja) 2011-10-14 2016-11-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 第ＸＩａ因子阻害剤としての置換テトラヒドロイソキノリン化合物
IN2014CN02806A (es) 2011-10-14 2015-07-03 Bristol Myers Squibb Co
AU2013305759C1 (en) * 2012-08-23 2018-01-18 Janssen Biopharma, Inc. Compounds for the treatment of paramoxyvirus viral infections
EP2906541B1 (en) 2012-10-12 2017-11-22 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
EA032092B1 (ru) 2012-10-12 2019-04-30 Бристол-Майерс Сквибб Компани Кристаллические формы ингибитора фактора xia
US9315519B2 (en) 2012-10-12 2016-04-19 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
JP6479763B2 (ja) 2013-03-25 2019-03-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 第ｘｉａ因子阻害剤としての置換アゾール含有のテトラヒドロイソキノリン
ES2687498T3 (es) 2014-01-31 2018-10-25 Bristol-Myers Squibb Company Macrociclos con grupos P2¿ heterocíclicos como inhibidores del factor XIa
NO2760821T3 (es) 2014-01-31 2018-03-10
PT3154594T (pt) 2014-06-13 2023-08-17 Bach Biosciences Llc Agentes terapêuticos ativados pela fap e utilizações relacionadas com os mesmos
WO2015192124A1 (en) 2014-06-13 2015-12-17 Trustees Of Tufts College Fap-activated therapeutic agents, and uses related thereto
ES2714283T3 (es) 2014-09-04 2019-05-28 Bristol Myers Squibb Co Macrociclos de diamida que son inhibidores de FXIa
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
MX2021006326A (es) 2015-09-17 2022-12-16 Inhibidores de pcna.
EP3459941A4 (en) 2016-07-22 2020-02-19 Kissei Pharmaceutical Co., Ltd. PYRROLIDINE DERIVATIVE
KR102590456B1 (ko) 2016-12-23 2023-10-17 씨에이에스피-에이드 인코포레이티드 카스파제-1 억제 및 신경학적 병태의 예방 및 치료를 위한 이의 용도
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
WO2020168294A1 (en) 2019-02-15 2020-08-20 Lysosomal And Rare Disorders Research And Treatment Center, Llc Methods and compositions for treating lysosomal storage disorders: ambroxol as treatment agent for mucopolysaccharidoses iii (sanfilippo syndrome)
US20230404972A1 (en) * 2020-11-25 2023-12-21 Lysosomal and Rare Disorders Research and Treatment Center, Inc. Inhibition of caspase pathway as a treatment for lysosomal storage disorders
WO2025226524A1 (en) * 2024-04-23 2025-10-30 Merck Sharp & Dohme Llc Granzyme b pet imaging agents

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2973111A (en) * 1958-02-11 1961-02-28 Dempster Brothers Inc Compaction bodies
US5874424A (en) 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US6204261B1 (en) * 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US4465679A (en) 1983-01-31 1984-08-14 Usv Pharmaceutical Corporation 1,2-Diaza-3-one compounds, their use in treating hypertension and pharmaceutical compositions thereof
IL72523A (en) 1983-08-12 1988-06-30 Takeda Chemical Industries Ltd 3-amino-4-oxo-2,3,4,5-tetrahydro-1,5-benzoxazepine derivatives,their production and pharmaceutical compositions containing them
US5055451A (en) 1986-12-22 1991-10-08 Syntex Inc. Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors
US5158936A (en) 1986-12-22 1992-10-27 Syntex (U.S.A.) Inc. Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors
US5008245A (en) 1988-10-27 1991-04-16 University Of Kentucky Research Foundation Novel peptidyl carbamate inhibitors of the enzyme elastase
CA2021660A1 (en) 1989-07-26 1991-01-27 Philippe Bey Peptidase inhibitors
NZ235155A (en) 1989-09-11 1993-04-28 Merrell Dow Pharma Peptidase substrates in which the carboxy terminal group has been replaced by a tricarbonyl radical
US5416013A (en) 1990-04-04 1995-05-16 Sterling Winthrop Inc. Interleukin 1β protease and interleukin 1β protease inhibitors
AU7775991A (en) 1990-04-04 1991-10-30 Immunex Corporation Interleukin 1beta protease
ATE172713T1 (de) 1991-03-15 1998-11-15 Hoechst Ag Verfahren zur diastereoselektiven reduktiven pinakol-kupplung von homochiralen alpha- aminoaldehyden
CA2071674C (en) * 1991-06-21 2003-08-19 Kevin T. Chapman Peptidyl derivatives as inhibitors of interleukin-1.beta. converting enzyme
JP3190431B2 (ja) 1991-07-01 2001-07-23 三菱化学株式会社 ケトン誘導体
US5278061A (en) 1991-08-16 1994-01-11 Merck & Co., Inc. Affinity chromatography matrix useful in purifying interleukin-1β converting enzyme
EP0533226A3 (en) 1991-08-16 1993-08-18 Merck & Co. Inc. Novel chromophore containing compounds
US6348570B1 (en) 1991-08-16 2002-02-19 Merck & Co., Inc. Chromophore containing compounds and their use in determining interleukin-1β convertase activity
DE69229252T2 (de) 1991-08-16 1999-12-16 Merck & Co., Inc. DNS, welche das Interleukin-1B-Vorläufer-Converting-Enzym kodiert
EP0600880B1 (en) 1991-08-30 2004-01-07 Vertex Pharmaceuticals Incorporated Interleukin 1- beta protease and interleukin 1-beta protease inhibitors
ATE140449T1 (de) 1991-10-07 1996-08-15 Hoechst Ag Verfahren zur diastereoselektiven reduktiven pinakol-kupplung von homochiralen alpha- aminoaldehyden
GB9123326D0 (en) 1991-11-04 1991-12-18 Sandoz Ltd Improvements in or relating to organic compounds
WO1993012076A1 (en) 1991-12-13 1993-06-24 Corvas International Inc. Reagents for automated synthesis of peptide analogs
EP0547699A1 (en) 1991-12-19 1993-06-23 Merck & Co. Inc. Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme
AU3479593A (en) 1992-01-31 1993-09-01 Merck & Co., Inc. Peptidyl derivatives as inhibitors of interleukin-1beta converting enzyme
ATE169224T1 (de) 1992-02-21 1998-08-15 Merck & Co Inc Peptidylderivate und inhibitoren des interleukin- 1-g(b)-konvertierenden enzyms
JPH08500242A (ja) 1992-06-24 1996-01-16 メルク エンド カンパニー インコーポレーテッド インターロイキン１β前駆体の転換酵素をコードするＤＮＡ
EP0654041B1 (en) 1992-07-31 1998-07-01 Pfizer Inc. Peptidyl 4-amino-2,2-difluoro-3-oxo-1,6-hexanedioic acid derivatives as antiinflammatory agents
CA2109646C (en) 1992-11-24 2000-03-07 Gaston O. Daumy Para-nitroanilide peptides
EP0618223A3 (en) 1993-03-08 1996-06-12 Sandoz Ltd Peptides, the release of Interleukin 1-Bêta, useful as anti-inflammatory agents.
CA2122227A1 (en) 1993-04-29 1994-10-30 Roland E. Dolle Peptide analogs as irreversible interleukin-1.beta. protease inhibitors
US5462939A (en) 1993-05-07 1995-10-31 Sterling Winthrop Inc. Peptidic ketones as interleukin-1β-converting enzyme inhibitors
US5411985A (en) 1993-05-17 1995-05-02 Merck & Co., Inc. Gamma-pyrone-3-acetic acid as an inhibitor or interleukin-1 β inventory enzyme
JPH0789951A (ja) 1993-06-03 1995-04-04 Sterling Winthrop Inc インターロイキン−１β転換酵素阻害剤
EP0644197B1 (en) 1993-06-04 1998-09-09 Vertex Pharmaceuticals Incorporated Peptidic phosphinyloxymethyl ketones as interleukin-1beta-converting enzyme inhibitors
WO1995000160A1 (en) 1993-06-24 1995-01-05 The General Hospital Corporation Programmed cell death genes and proteins
US5866545A (en) 1993-08-13 1999-02-02 Merck & Co., Inc. Substituted ketone derivatives as inhibitors of interleukin-1β converting enzyme
ES2114113T3 (es) * 1993-11-11 1998-05-16 Basf Ag Derivados de p-hidroxianilina, procedimiento para su obtencion y su empleo para la lucha contra los hongos dañinos y contra las pestes.
US5714484A (en) 1993-12-08 1998-02-03 Prototek, Inc. α-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors
US5486623A (en) 1993-12-08 1996-01-23 Prototek, Inc. Cysteine protease inhibitors containing heterocyclic leaving groups
CN1504462A (zh) 1994-03-31 2004-06-16 ������˹ҩƷ��˾ 作为白细胞介素抑制剂的嘧啶基衍生物
CA2189036A1 (en) 1994-04-29 1995-11-09 Roland E. Dolle Halomethyl amides as il-1.beta. protease inhibitors
US5492824A (en) 1994-05-12 1996-02-20 Basf Ag Ice and ice-like compositions and methods of making same
US5552400A (en) 1994-06-08 1996-09-03 Sterling Winthrop Inc. Fused-bicyclic lactams as interleukin-1β converting enzyme inhibitors
US5716929A (en) * 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5756466A (en) 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5847135A (en) 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US5856116A (en) 1994-06-17 1999-01-05 Vertex Pharmaceuticals, Incorporated Crystal structure and mutants of interleukin-1 beta converting enzyme
US5565430A (en) 1994-08-02 1996-10-15 Sterling Winthrop Inc. Azaaspartic acid analogs as interleukin-1β converting enzyme inhibitors
GB2292149A (en) * 1994-08-09 1996-02-14 Ferring Res Ltd Peptide inhibitors of pro-interleukin-1beta converting enzyme
US5498616A (en) 1994-11-04 1996-03-12 Cephalon, Inc. Cysteine protease and serine protease inhibitors
TW394764B (en) 1995-02-14 2000-06-21 Mitsubishi Chemcal Corp Oxygen-containing heterocyclic derivatives
JPH09165360A (ja) * 1995-03-31 1997-06-24 Takeda Chem Ind Ltd システインプロテアーゼ阻害剤
CA2215211A1 (en) 1995-03-31 1996-10-03 Takeda Chemical Industries, Ltd. Cysteine protease inhibitor
US5798442A (en) 1995-04-21 1998-08-25 Merck Frosst Canada, Inc. Peptidyl derivatives as inhibitors of pro-apoptotic cysteine proteinases
EP0851760A4 (en) 1995-08-31 1998-11-25 Smithkline Beecham Corp INTERLEUKIN CONVERSION ENZYME AND APOPTOSIS
EP0859779A4 (en) 1995-08-31 2000-04-12 Smithkline Beecham Corp INTERLEUKIN CONVERSION ENZYME AND APOPTOSIS
EP0761680A3 (en) 1995-09-12 1999-05-06 Ono Pharmaceutical Co., Ltd. Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity
US5744451A (en) 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
US6136834A (en) * 1995-12-27 2000-10-24 Ono Pharmaceutical Co., Ltd. Tetrazole compounds and pharmaceutical agents containing such derivative
WO1998001133A1 (en) 1996-07-08 1998-01-15 Yamanouchi Pharmaceutical Co., Ltd. Bone resorption inhibitors
WO1998004539A1 (en) 1996-07-29 1998-02-05 Mitsubishi Chemical Corporation Oxygenic heterocyclic derivatives
US5869519A (en) * 1996-12-16 1999-02-09 Idun Pharmaceuticals, Inc. C-terminal modified (n-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
AU739496B2 (en) 1996-09-12 2001-10-11 Idun Pharmaceuticals, Incorporated Novel tricyclic compounds for the inhibition of the ice/ced-3 protease family of enzymes
DE69734718T2 (de) 1996-09-12 2006-08-24 Idun Pharmaceuticals, Inc., San Diego Hemmung der apoptose unter verwendung von inhibitoren der interleukin-1 beta converting enzym (ice)/ced-3 familie
AU739321B2 (en) * 1996-09-12 2001-10-11 Idun Pharmaceuticals, Incorporated C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US5968927A (en) * 1996-09-20 1999-10-19 Idun Pharmaceuticals, Inc. Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes
US5877197A (en) * 1996-12-16 1999-03-02 Karanewsky; Donald S. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6184244B1 (en) * 1996-12-16 2001-02-06 Idun Pharmaceuticals, Inc. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
HUP9700816A3 (en) 1997-04-28 1999-06-28 Gyogyszerkutato Intezet 3(r)-3-amino-4-carboxy-butiraldehyde derivatives inhibiting release of interleukin-1-beta
US6184210B1 (en) * 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
ES2229545T3 (es) * 1997-10-31 2005-04-16 Kimberly-Clark Worldwide, Inc. Materiales no tejidos, rizados y recubrimiento.
ID27002A (id) * 1998-03-19 2001-02-22 Vertex Pharma Penghambat-penghambat kaspase
US6197750B1 (en) * 1998-07-02 2001-03-06 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6242422B1 (en) * 1998-10-22 2001-06-05 Idun Pharmacueticals, Inc. (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
PE20011350A1 (es) * 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
CA2545733A1 (en) * 2003-11-10 2005-05-26 Vertex Pharmaceuticals Incorporated Methods for monitoring il-18
EP1718639A2 (en) * 2004-02-27 2006-11-08 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
EP2295054A1 (en) * 2004-05-27 2011-03-16 Vertex Pharmaceuticals Incorporated Ice inhibitors for the treatment of autoinflammatory diseases

Also Published As

Publication number Publication date
NO20004546L (no) 2000-11-09
AU3098699A (en) 1999-10-11
BRPI9909660B1 (pt) 2018-09-18
CZ20003409A3 (cs) 2001-01-17
KR100898094B1 (ko) 2009-05-18
EP2011800A2 (en) 2009-01-07
EP1064298B1 (en) 2008-10-08
EP2261232A2 (en) 2010-12-15
UA96113C2 (en) 2011-10-10
ZA200004652B (en) 2002-04-24
IL138469A (en) 2010-11-30
EP2261232A3 (en) 2011-04-20
EP2261233A3 (en) 2011-04-20
KR20010042038A (ko) 2001-05-25
JP2002506878A (ja) 2002-03-05
US20030232986A1 (en) 2003-12-18
PT1064298E (pt) 2009-01-02
NO331829B1 (no) 2012-04-16
SK286736B6 (sk) 2009-04-06
EP2011800A3 (en) 2009-06-24
ES2315010T3 (es) 2009-03-16
RU2274642C2 (ru) 2006-04-20
CN1321129C (zh) 2007-06-13
KR100928878B1 (ko) 2009-11-30
WO1999047545A2 (en) 1999-09-23
JP2010241822A (ja) 2010-10-28
SK13822000A3 (sk) 2001-04-09
BG104863A (en) 2001-04-30
KR20080020703A (ko) 2008-03-05
TR200103406T2 (tr) 2002-06-21
ATE410439T1 (de) 2008-10-15
NZ506963A (en) 2003-10-31
TWI243828B (en) 2005-11-21
IL206621A0 (en) 2010-12-30
JP2006206600A (ja) 2006-08-10
US7358273B2 (en) 2008-04-15
EP1064298A2 (en) 2001-01-03
ID27002A (id) 2001-02-22
NO20004546D0 (no) 2000-09-12
AP2000001919A0 (en) 2000-09-30
HK1035733A1 (en) 2001-12-07
EP2261233A2 (en) 2010-12-15
IL138469A0 (en) 2001-10-31
EP2261234A2 (en) 2010-12-15
PL343611A1 (en) 2001-08-27
US8691848B2 (en) 2014-04-08
WO1999047545A3 (en) 1999-11-25
PL204619B1 (pl) 2010-01-29
EP2261235A2 (en) 2010-12-15
CZ302281B6 (cs) 2011-01-26
JP4594520B2 (ja) 2010-12-08
AU769033B2 (en) 2004-01-15
BRPI9909660B8 (pt) 2021-05-25
UA74133C2 (uk) 2005-11-15
GEP20043163B (en) 2004-01-26
EP2261235A3 (en) 2011-04-20
CA2324226A1 (en) 1999-09-23
NZ528282A (en) 2005-05-27
HU227920B1 (en) 2012-06-28
HUP0103575A2 (hu) 2002-02-28
HUP0103575A3 (en) 2002-10-28
EP2261234A3 (en) 2011-04-20
BR9909660A (pt) 2000-11-21
CN1323314A (zh) 2001-11-21
SI1064298T1 (sl) 2009-02-28
CA2324226C (en) 2012-06-05
US6531474B1 (en) 2003-03-11
DE69939689D1 (de) 2008-11-20
IS5622A (is) 2000-09-08
DK1064298T3 (da) 2009-01-19
US20090048226A1 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
AR019011A1 (es) Inhibidores de las caspasas, composiciones farmaceuticas que comprenden estos inhibidores, metodos para inhibir la actividad de caspasa, disminuir laproduccion de 161f, disminuir la produccion de ifn-gama y para tratar interleukina 1, enfermedades mediadas por apoptosis e interferon-gama usando dich
NO961888D0 (no) Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer av metallproteinaser
ATE346085T1 (de) Inhibitoren des interleukin-1-beta konvertierenden enzyms
PT1119362E (pt) Metodos de utilizacao de compostos tetraciclina para aumentar a producao de interleucina-10
ATE366722T1 (de) Substituierte pyridin-derivate als entzündungshemmende mittel
EP1551812A4 (en) MITOTIC KINESINE HEMMER
ATE447577T1 (de) Mitotische kinesin-hemmer
ATE372341T1 (de) Inhibitoren von mitotischem kinesin
DE69635458T2 (de) Inhibitoren des interleukin-1-beta konvertierenden enzyms
DK1042293T3 (da) Substituerede pyridin- og pyridazinforbindelser og deres farmaceutiske anvendelse
ATE421512T1 (de) Inhibitoren von mitotischem kinesin
EP1515724A4 (en) MITOTIC KINESINE HEMMER
ATE430193T1 (de) Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen
ATE266675T1 (de) Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese
ATE329587T1 (de) Zusammensetzungen zur verwendung bei der behandlung der osteoporose und/oder der entzündlichen gelenkerkrankungen
ATE311853T1 (de) Verwendung von krillenzymen zur behandlung von zahnbelag
ATE296812T1 (de) 1,2-diazepanderivate als inhibitoren des interleukin-1beta umwandelnden enzyms
DE69732712D1 (de) INHIBITOREN DES INTERLEUKIN-1beta KONVERTIERENDEN ENZYMS
NO20052272L (no) CCR1-antagonister for behandling av blant annet demylinerene inflamasjonssykdom
DE60008753D1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
DK1284977T3 (da) Thienodibenzoazulenforbindelser som tumornekrosefaktorhæmmere
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
ES2189165T3 (es) Nuevos compuestos macrociclicos como inhibidores de metaloproteasa.
ATE428781T1 (de) Oligonukleotid-zusammansetzungen und deren verwendung zur induzierung von apoptose
ES2157923T3 (es) Compuestos utiles para tratar enfermedades alergicas e inflamatorias.

Legal Events

Date Code Title Description
FG Grant, registration